International Journal of Colorectal Disease

, Volume 24, Issue 6, pp 605–612

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

  • Emmanuel Mitry
  • Astrid Lièvre
  • Jean-Baptiste Bachet
  • Philippe Rougier
Review

Abstract

Background

Patients with metastatic colorectal cancer (mCRC) who progress despite treatment with fluoropyrimidine and irinotecan or oxaliplatin have diminished survival, but they may derive clinically meaningful benefit from second-line or later chemotherapy.

Materials and methods

Literature from 2000 through mid-2008 on the treatment of patients with unresectable mCRC was reviewed to identify options for chemotherapy-resistant patients with mCRC.

Results and conclusions

A recurring finding is that overall survival increases when patients are exposed to all available active agents throughout their course of care, independent of the line of treatment in which medication is delivered. Sequential administration of agents, including irinotecan, oxaliplatin, bevacizumab, and cetuximab, or, alternatively, deferred administration of various medications in combination, have shown promising efficacy that is at least equivalent to established combination regimens with the same agents. Palliative chemotherapy clearly improves survival in patients with unresectable mCRC, with overall survival recently reaching 28 months.

Keywords

Bevacizumab Capecitabine Combination treatment FOLFIRI FOLFOX Targeted agents 

References

  1. 1.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592PubMedCrossRefGoogle Scholar
  2. 2.
    Europe against colorectal cancer. Declaration of Brussels, May 9, 2007. Available via http://www.future-health-2007.com Accessed 14 Aug 2008
  3. 3.
    American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society 2008. Available via http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed 14 Aug 2008
  4. 4.
    Ragnhammar P, Hafstrom L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282–308PubMedCrossRefGoogle Scholar
  5. 5.
    Massacesi C, Pistilli B, Valeri M et al (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25:140–148PubMedCrossRefGoogle Scholar
  6. 6.
    Massacesi C, Norman A, Price T, Hill M, Ross P, Cunningham D (2000) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36:2044–2052PubMedCrossRefGoogle Scholar
  7. 7.
    Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1061PubMedCrossRefGoogle Scholar
  8. 8.
    Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMedCrossRefGoogle Scholar
  9. 9.
    Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRefGoogle Scholar
  10. 10.
    Masi G, Marcucci L, Loupakis F et al (2006) First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 17:1249–1254PubMedCrossRefGoogle Scholar
  11. 11.
    Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676PubMedCrossRefGoogle Scholar
  12. 12.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  13. 13.
    Grothey A, Marshall JL (2007) Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology (Williston Park) 21:553–564Google Scholar
  14. 14.
    Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRefGoogle Scholar
  15. 15.
    Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26:689–690PubMedCrossRefGoogle Scholar
  16. 16.
    Chau I, Norman AR, Cunningham D et al (2004) Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91:1453–1458PubMedCrossRefGoogle Scholar
  17. 17.
    Lal R, Dickson J, Cunningham D et al (2004) A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 22:3023–3031PubMedCrossRefGoogle Scholar
  18. 18.
    Van Cutsem E, Dirix L, Van Laethem J-L et al (2005) Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 92:1055–1062PubMedCrossRefGoogle Scholar
  19. 19.
    Bamias A, Papamichael D, Syrigos K, Pavlidis N (2003) Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother 15:275–281PubMedGoogle Scholar
  20. 20.
    Scheithauer W, Kornek GV, Brugger S et al (2002) Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 20:60–68PubMedCrossRefGoogle Scholar
  21. 21.
    Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA (2002) Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216–1220PubMedCrossRefGoogle Scholar
  22. 22.
    Rougier P, Lepille D, Bennouna J et al (2002) Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 13:1558–1567PubMedGoogle Scholar
  23. 23.
    Twelves C (2002) Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 16(12 Suppl No 14):23–26Google Scholar
  24. 24.
    Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292PubMedGoogle Scholar
  25. 25.
    Scheithauer W, McKendrick J, Begbie S et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743PubMedCrossRefGoogle Scholar
  26. 26.
    Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106PubMedGoogle Scholar
  27. 27.
    Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142PubMedCrossRefGoogle Scholar
  28. 28.
    Hoff PM, Pazdur R, Lassere Y et al (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22:2078–2083PubMedCrossRefGoogle Scholar
  29. 29.
    Pfeiffer P, Sorbye H, Ehrsson H et al (2006) Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 17:252–258PubMedCrossRefGoogle Scholar
  30. 30.
    Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786PubMedCrossRefGoogle Scholar
  31. 31.
    Hofheinz RD, Gnad-Vogt U, Wein A et al (2005) Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anticancer Drugs 16:39–45PubMedCrossRefGoogle Scholar
  32. 32.
    Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544PubMedCrossRefGoogle Scholar
  33. 33.
    Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ (2007) Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 13:6231–6235PubMedCrossRefGoogle Scholar
  34. 34.
    Lièvre A, Samalin E, Senesse P (2007) Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as second-line, third-line or later treatment in metastatic colorectal cancer (MCRC) patients. J Clin Oncol 25: Abstract 14558Google Scholar
  35. 35.
    Lenz HJ, Van CE, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921PubMedCrossRefGoogle Scholar
  36. 36.
    Jonker DJ, O’Callaghan CJ (2007) Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048PubMedCrossRefGoogle Scholar
  37. 37.
    Adam R, Aloia T, Levi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–4602PubMedCrossRefGoogle Scholar
  38. 38.
    Lim RS, Sun Y, Im SA et al (2007) Cetuximab in combination with irinotecan in the treatment of patients (pts) with metastatic colorectal carcinoma (mCRC) refractory to irinotecan: Preliminary data from the ELSIE study. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19–21, Orlando, FL. Abstract 371Google Scholar
  39. 39.
    Fagnani D, Bertolini A, Menatti E et al (2007) Cetuximab and irinotecan (CPT11) salvage treatment for colorectal cancer (CRC) in progression after two or more chemotherapy (CT) lines: The POLONORD Group experience. J Clin Oncol 25: Abstract 14575Google Scholar
  40. 40.
    Bouchahda M, Macarulla T, Spano JP et al (2007) Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. J Clin Oncol 25: Abstract 14528Google Scholar
  41. 41.
    Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792–797PubMedCrossRefGoogle Scholar
  42. 42.
    Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561PubMedCrossRefGoogle Scholar
  43. 43.
    Punt CJ, Tol J, Rodenburg CJ et al (2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(suppl): Abstract LBA4011Google Scholar
  44. 44.
    Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379PubMedCrossRefGoogle Scholar
  45. 45.
    Van Cutsem E, Lang I, D’haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26: Abstract 2Google Scholar
  46. 46.
    Folprecht G, Lutz MP, Schöffski P et al (2005) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456PubMedCrossRefGoogle Scholar
  47. 47.
    Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664PubMedCrossRefGoogle Scholar
  48. 48.
    Hecht JR, Mitchell E, Chidiac T et al (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). American Society of Clinical Oncology Gastrointestinal Symposium; June 25–27, Orlando, Florida. Abstract 273Google Scholar
  49. 49.
    Mitchell EP, LaCouture M, Shearer H et al (2008) A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving 2nd line FOLFIRI or irinotecan-only chemotherapy (CT) with panitumumab (pmab): Early analysis. American Society of Clinical Oncology Gastrointestinal Symposium; June 25–27 Orlando, Florida. Abstract 462Google Scholar
  50. 50.
    Markman M (2008) Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue? Curr Oncol Rep 10:93–94PubMedCrossRefGoogle Scholar
  51. 51.
    Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898–911PubMedCrossRefGoogle Scholar
  52. 52.
    Hobday TJ, Goldberg RM (2002) Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer 2:161–169PubMedCrossRefGoogle Scholar
  53. 53.
    Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453–1459PubMedCrossRefGoogle Scholar
  54. 54.
    Seymour MT, Maughan TS, Ledermann JA et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370:143–152PubMedCrossRefGoogle Scholar
  55. 55.
    Bouche O, Castaing M, Etienne PL et al (2007) Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. J Clin Oncol 25: Abstract 4069Google Scholar
  56. 56.
    Souglakos J, Androulakis N, Syrigos K et al (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798–805PubMedCrossRefGoogle Scholar
  57. 57.
    Braun MS, Quirke P, Seymour MT (2007) Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Rev Anticancer Ther 7:489–501PubMedCrossRefGoogle Scholar
  58. 58.
    Casado E, De CJ, Belda-Iniesta C et al (2007) Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol 9:549–554PubMedCrossRefGoogle Scholar
  59. 59.
    Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130PubMedCrossRefGoogle Scholar
  60. 60.
    Shankaran V, Wisinski KB, Mulcahy MF, Benson AB (2008) The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 12:87–98PubMedGoogle Scholar
  61. 61.
    Wright CM, Dent OF, Barker M et al (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197–1202PubMedCrossRefGoogle Scholar
  62. 62.
    Miller CR, McLeod HL (2007) Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 5:9–14PubMedGoogle Scholar
  63. 63.
    Brueckl WM, Moesch C, Brabletz T et al (2003) Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23:1773–1777PubMedGoogle Scholar
  64. 64.
    Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Emmanuel Mitry
    • 1
  • Astrid Lièvre
    • 2
  • Jean-Baptiste Bachet
    • 1
  • Philippe Rougier
    • 1
  1. 1.Hépatogastroentérologie et oncologie digestiveHôpital Ambroise ParéBoulogneFrance
  2. 2.Inserm UMR-S775, Bases moléculaires de la réponse aux xénobiotiquesUniversité Paris-DescartesParisFrance

Personalised recommendations